| Literature DB >> 27830083 |
Reza Shafiei1, Saeed Hosseini Teshnizi2, Kurosh Kalantar3, Maryam Gholami1, Golnush Mirzaee4, Fatemeh Mirzaee5.
Abstract
Human cystic echinococcosis (HCE), a zoonotic infection of the larval stage of Echinococcus granulosus, has high effect on public health in human population all around the world. Iran is one of the most important endemic areas in the Middle East. This systematic review and meta-analysis was performed to evaluate the seroprevalence of HCE in Iranian population. An electronic search for articles from 1985 until April 2015 was performed using data bases PubMed, Scopus, Google Scholar, Magiran, IranMedex, Iran Doc, and Scientific Information Database (SID) both in English and in Persian. A random-effects meta-analysis was used to combine results from individual studies. The information was analyzed by STATA version 11.1. A total of 33 articles met our eligibility criteria and were included in a meta-analysis. The pooled estimate of the prevalence of HCE based on random-effects model was estimated 6.0% (95% CI: 4.0%, 7.0%). The prevalence of the disease significantly increased with age and prevalence rate in males was significantly lower than females (p < 0.001). The using of CIE or CCIEP method was also significantly greater than the other methods (p < 0.001). There was a publication bias in prevalence of studies. HCE is highly prevalent in Iran. Public education for preventive strategies and finally reducing transmission of the parasite and infection in population is needed.Entities:
Year: 2016 PMID: 27830083 PMCID: PMC5086504 DOI: 10.1155/2016/1425147
Source DB: PubMed Journal: J Parasitol Res ISSN: 2090-0023
Figure 1PRISMA flowchart describing the study design process.
Figure 2Graphic representation of prevalence (%) of HCE in provinces in Iran. The asterisk (∗) means the minimum and maximum of prevalence in province.
General characteristics of studies included in the present systematic review and meta-analysis.
| Author [reference] | Year | Province | sample | Positive | Positive | Lab method (Ag) | Target group |
|---|---|---|---|---|---|---|---|
| Jamali [ | 1995 | Uromieh | 300 | 5 | 1.67 (0.22, 3.12) | IFA | Villagers |
| Arbabi [ | 1998 | Hamedan | 1530 | 46 | 3.01 (2.15, 3.86) | IFA | Healthy volunteers |
| Saberi-Firouzi [ | 1998 | Fars | 1000 | 137 | 13.70 (11.57, 15.83) | CIE | Healthy volunteers |
| Mohamadi [ | 1998 | Tehran | 700 | 68 | 9.71 (7.52, 11.91) | IFA | Healthy volunteers |
| Zariffard [ | 1999 | Western Iran | 4138 | 230 | 5.56 (4.86, 6.26) | ELISA | Healthy volunteers |
| Nilfroshan [ | 1998 | Esfehan | 1000 | 36 | 3.60 (2.45, 4.75) | IFA | Healthy volunteers |
| Sadjjadi [ | 2001 | Shiraz | 1227 | 76 | 6.19 (4.85, 7.54) | CCIEP | Healthy volunteers |
| Sedaghat Gohar [ | 2001 | Tehran | 1052 | 62 | 5.89 (4.47, 7.32) | IFA | Healthy volunteers |
| Yousefi Darani [ | 2003 | Chaharmahal | 2524 | 120 | 4.75 (3.92, 5.58) | CIE | Surgical patients |
| Amiri [ | 2001 | Kermanshah | 1072 | 86 | 8.02 (6.4, 9.65) | IFA | Patients and blood donors |
| Farrokhzad [ | 2004 | Tehran | 437 | 1 | 0.23 (−0.22, 0.68) | IFA | Healthy volunteers |
| Haniloo [ | 2002 | Zanjan | 2367 | 71 | 3.00 (2.31, 3.69) | ELISA | Healthy volunteers |
| Aflaki [ | 2005 | Eilam | 3000 | 37 | 1.23 (0.84, 1.63) | Dot-ELISA | Healthy volunteers |
| Rafiei [ | 2005 | Khuzestan | 4596 | 437 | 9.51 (8.66, 10.36) | ELISA | Healthy volunteers |
| Akhlaghi [ | 2005 | Kordestan | 1114 | 37 | 3.32 (2.27, 4.37) | IFA | Healthy volunteers |
| Rafiei [ | 2007 | Khuzestan | 3446 | 475 | 13.78 (12.63, 14.94) | ELISA | Healthy volunteers |
| Baharsefat [ | 2007 | Golestan | 1024 | 46 | 4.49 (3.22, 5.76) | ELISA, IFA | Healthy volunteers |
| Mirzanejadasl [ | 2008 | Ardabil | 1003 | 111 | 11.07 (9.13, 13.01) | ELISA | Healthy volunteers |
| Hadadian [ | 2008 | Kordestan | 1979 | 22 | 1.11 (0.65, 1.57) | ELISA | Healthy volunteers |
| Moazezi [ | 2009 | Kerman | 451 | 37 | 8.20 (5.67, 10.74) | ELISA | Blood donors |
| Akhlaghi [ | 2009 | Tehran | 1100 | 18 | 1.64 (0.01, 0.02) | Dot-ELISA | Healthy volunteers |
| Esmaeili [ | 2010 | Kashan | 361 | 11 | 3.05 (0.01, 0.05) | ELISA, IFA | Healthy volunteers |
| Srakari [ | 2010 | Yasuj | 500 | 36 | 7.20 (0.05, 0.09) | ELISA | Patients referred to lab |
| Dadkhah [ | 2011 | East Azarbaijan | 250 | 8 | 3.20 (0.01, 0.05) | IFA | Healthy volunteers |
| Harandi [ | 2011 | Kerman | 1140 | 34 | 2.98 (0.02, 0.04) | ELISA | Healthy volunteers |
| Kavous [ | 2010 | Jahrom | 1096 | 69 | 6.30 (0.05, 0.08) | ELISA | Patients referred to lab |
| Garedaghi [ | 2011 | East Azarbaijan | 1500 | 11 | 0.73 (0, 0.01) | ELISA | Healthy volunteers |
| Heidari [ | 2011 | Ardabil | 670 | 12 | 1.79 (0.01, 0.03) | ELISA | Healthy volunteers |
| Rakhshanpour [ | 2012 | Qom | 1564 | 25 | 1.60 (0.01, 0.02) | ELISA | Healthy volunteers |
| Zibaei [ | 2013 | Khorram abad | 617 | 95 | 15.40 (0.13, 0.18) | ELISA | Patients referred to lab |
| Asgari [ | 2013 | Arak | 578 | 20 | 3.46 (0.02, 0.05) | ELISA | Healthy volunteers |
| Shahrokhabadi [ | 2014 | Kerman | 486 | 9 | 1.85 (0.01, 0.03) | ELISA | Patients referred to HC |
| Ilbeigi [ | 2015 | Isfahan | 635 | 7 | 1.10 (0, 0.02) | ELISA | Patients referred to HC |
N: number of positive; HC: health center.
Figure 3Forest plot of meta-analysis results for prevalence of CE. The middle point of each line indicates the prevalence rate and the length of line indicates 95% confidence interval of each study. Rhombus shape indicates 95% confidence interval for all studies.
Subgroup meta-analysis of cystic echinococcosis for age, sex, and lab methods.
| Variable | Number | Prevalence | 95% CI |
|
|
| |
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Age (year) | |||||||
| <30 | 7 | 2.2 | 1.9 | 3.3 | 93.2% | 862.8 |
|
| 30–40 | 9 | 2.8 | 2.1 | 4.2 | 94.5% | ||
| >40 | 6 | 4.1 | 3.0 | 4.8 | 98.7% | ||
|
| |||||||
| Sex | |||||||
| Male | 21 | 2.1 | 1.8 | 2.4 | 94.9% | 398.1 |
|
| Female | 10 | 3.6 | 3.2 | 3.9 | 96.2% | ||
|
| |||||||
| Lab methods | |||||||
| CIE | 3 | 6.0 | 5.3 | 6.7 | 96.6% | 720.9 |
|
| ELISA | 15 | 3.2 | 3.0 | 3.4 | 98.6% | ||
| IFA | 9 | 2.2 | 1.8 | 2.5 | 97.4% | ||
| ELISA & Others | 4 | 1.8 | 1.5 | 2.1 | 91.8% | ||